Search results for "Lentiviral Vectors"
Article
Lentiviral Vector Upstream Process in Single-use Bioreactors
However, cost-effective manufacturing of lentiviral vectors at commercial scales has proven difficult and remains a pressing issue for the marketing of therapies that depend on their application.
Article
Improving Lentiviral Vector Downstream Processing Workflows
Lentiviral vectors (LVV) are a common vehicle to deliver genetic material in chimeric antigen receptor (CAR) T-cell therapy and gene therapy applications. Production methods have been developed by a…
Article
Gene Therapies Push Viral Vector Production
Lentiviral vectors, meanwhile, are a subgroup of retroviral vectors. Lentiviral vectors have displaced traditional retroviral vectors because lentiviral vectors do not require dividing host cells for …
Article
Single-Use Technologies Prove Effective for Viral Vector Process Development
The benefits of single-use technologies for upstream viral-vector processes clearly outweigh their disadvantages.
Cynthia A. Challener
Upstream viral-vector processes can have sig…
Article
A Look at the Affinity Chromatography Landscape
The greatest demand is for lentiviral and adeno-associated viral (AAV) vectors, with sourcing of lentiviral vectors becoming a bottleneck for gene and cell therapy manufacturing.
Traditionally,…
Article
Process Development: 2020 Reflections and 2021 Possibilities
Addressing pain points for lentiviral vectors, which are used as a common vehicle to deliver genetic material in chimeric antigen receptor (CAR) T-cell therapy and gene therapy applications, by creati…
Article
Getting Ahead of the Game in Cell and Gene Therapy
Successes in the clinic have placed many cell and gene therapies on an accelerated route to market. But unless developers consider, at an early stage, how they might produce their product at scale, th…
Article
FDA Seeks to Enhance Manufacturing of Cell and Gene Therapies
FDA Seeks to Enhance Manufacturing of Cell and Gene Therapies
More consistent and reliable production processes are critical for advancing innovative treatments.
By Jill Wechsler
…